A framework of biomarkers for brain aging: a consensus statement by the Aging Biomarker Consortium

Abstract

China and the world are facing severe population aging and an increasing burden of age-related diseases. Aging of the brain causes major age-related brain diseases, such as neurodegenerative diseases and stroke. Identifying biomarkers for the effective assessment of brain aging and establishing a brain aging assessment system could facilitate the development of brain aging intervention strategies and the effective prevention and treatment of aging-related brain diseases. Thus, experts from the Aging Biomarker Consortium (ABC) have combined the latest research results and practical experience to recommend brain aging biomarkers and form an expert consensus, aiming to provide a basis for assessing the degree of brain aging and conducting brain-aging-related research with the ultimate goal of improving the brain health of elderly individuals in both China and the world.

References

[1] Cai Y, Song W, Li J, et al. The landscape of aging. Sci China Life Sci 2022;65:2354–454.

[2] Aging Biomarker C et al. Biomarkers of aging. Sci China Life Sci 2023;66(5):893–1066.

[3] Sousa-Uva M, Head SJ, Thielmann M, et al. Methodology manual for European Association for Cardio-Thoracic Surgery (EACTS) clinical guidelines. Eur J Cardiothorac Surg 2015;48:809–16.

[4] Li H, Lv C, Zhang T, et al. Trajectories of age-related cognitive decline and potential associated factors of cognitive function in senior citizens of Beijing. Curr Alzheimer Res 2014;11:806–16.

[5] Tromp D, Dufour A, Lithfous S, et al. Episodic memory in normal aging and Alzheimer disease: insights from imaging and behavioral studies. Ageing Res Rev 2015;24:232–62.

[6] Nyberg L. Functional brain imaging of episodic memory decline in ageing. J Intern Med 2017;281:65–74.

[7] Lempert KM, Cohen MS, MacNear KA, et al. Aging is associated with maladaptive episodic memory-guided social decision-making. Proc Natl Acad Sci U S A 2022;119:e2208681119.

[8] Pelletier A, Bernard C, Dilharreguy B, et al. Patterns of brain atrophy associated with episodic memory and semantic fluency decline in aging. Aging (Albany NY) 2017;9:741–52.

[9] Persson J, Nyberg L, Lind J, et al. Structure-function correlates of cognitive decline in aging. Cereb Cortex 2006;16:907–15.

[10] Charlton RA, Barrick TR, Markus HS, et al. The relationship between episodic long-term memory and white matter integrity in normal aging. Neuropsychologia 2010;48:114–22.

[11] Ousdal OT, Kaufmann T, Kolskår K, et al. Longitudinal stability of the brain functional connectome is associated with episodic memory performance in aging. Hum Brain Mapp 2020;41:697–709.

[12] Nyberg L, Sandblom J, Jones S, et al. Neural correlates of training-related memory improvement in adulthood and aging. Proc Natl Acad Sci U S A 2003;100:13728–33.

[13] Dennis NA, Daselaar S, Cabeza R. Effects of aging on transient and sustained successful memory encoding activity. Neurobiol Aging 2007;28:1749–58.

[14] Grady CL, McIntosh AR, Horwitz B, et al. Age-related reductions in human recognition memory due to impaired encoding. Science 1995;269:218–21.

[15] Wang L, Li H, Liang Y, et al. Amnestic mild cognitive impairment: topological reorganization of the default-mode network. Radiology 2013;268:501–14.

[16] Benejam B, Aranha MR, Videla L, et al. Neural correlates of episodic memory in adults with Down syndrome and Alzheimer’s disease. Alzheimers Res Ther 2022;14:123.

[17] Moradi E, Hallikainen I, Hänninen T, et al; Alzheimer’s Disease Neuroimaging Initiative. Rey’s Auditory Verbal Learning Test scores can be predicted from whole brain MRI in Alzheimer’s disease. Neuroimage Clin 2017;13:415–27.

[18] Lacreuse A, Raz N, Schmidtke D, et al. Age-related decline in executive function as a hallmark of cognitive ageing in primates: an overview of cognitive and neurobiological studies. Philos Trans R Soc Lond B Biol Sci 2020;375:20190618.

[19] Geerligs L, Saliasi E, Maurits NM, et al. Brain mechanisms underlying the effects of aging on different aspects of selective attention. Neuroimage 2014;91:52–62.

[20] Zelinski EM, Burnight KP. Sixteen-year longitudinal and time lag changes in memory and cognition in older adults. Psychol Aging 1997;12:503–13.

[21] Park DC, Lautenschlager G, Hedden T, et al. Models of visuospatial and verbal memory across the adult life span. Psychol Aging 2002;17:299–320.

[22] Hoogendam YY, Hofman A, van der Geest JN, et al. Patterns of cognitive function in aging: the Rotterdam Study. Eur J Epidemiol 2014;29:133–40.

[23] Verhaeghen P, Salthouse TA. Meta-analyses of age-cognition relations in adulthood: estimates of linear and nonlinear age effects and structural models. Psychol Bull 1997;122:231–49.

[24] Elliott ML, Belsky DW, Knodt AR, et al. Brain-age in midlife is associated with accelerated biological aging and cognitive decline in a longitudinal birth cohort. Mol Psychiatry 2021;26:3829–38.

[25] Beker N, Ganz A, Hulsman M, et al. Association of cognitive function trajectories in centenarians with postmortem neuropathology, physical health, and other risk factors for cognitive decline. JAMA Netw Open 2021;4:e2031654.

[26] Llinàs-Reglà J, Vilalta-Franch J, López-Pousa S, et al. The trail making test. Assessment 2017;24:183–96.

[27] Fett AJ, Velthorst E, Reichenberg A, et al. Long-term changes in cognitive functioning in individuals with psychotic disorders: findings from the Suffolk county mental health project. JAMA Psychiatry 2020;77:387–96.

[28] Hoogendam YY, van der Lijn F, Vernooij MW, et al. Older age relates to worsening of fine motor skills: a population-based study of middle-aged and elderly persons. Front Aging Neurosci 2014;6:259–265.

[29] Quandt F, Bönstrup M, Schulz R, et al. Spectral variability in the aged brain during fine motor control. Front Aging Neurosci 2016;8:305.

[30] Ferdon S, Murphy C. The cerebellum and olfaction in the aging brain: a functional magnetic resonance imaging study. Neuroimage 2003;20:12–21.

[31] Dintica CS, Marseglia A, Rizzuto D, et al. Impaired olfaction is associated with cognitive decline and neurodegeneration in the brain. Neurology 2019;92:e700–9.

[32] Dong Y, Li Y, Liu K, et al. Anosmia, mild cognitive impairment, and biomarkers of brain aging in older adults. Alzheimers Dement 2023;19:589–601.

[33] Volkert J, Schulz H, Härter M, et al. The prevalence of mental disorders in older people in Western countries—a meta-analysis. Ageing Res Rev 2013;12:339–53.

[34] AM NM et al. Frailty, depression, and anxiety in later life. Int Psychogeriatr 2012;24:1265–74.

[35] Prenderville JA, Kennedy PJ, Dinan TG, et al. Adding fuel to the fire: the impact of stress on the ageing brain. Trends Neurosci 2015;38:13–25.

[36] Shafto MA, Tyler LK. Language in the aging brain: the network dynamics of cognitive decline and preservation. Science 2014;346:583–7.

[37] Fabricio DM, Chagas MHN, Diniz BS. Frailty and cognitive decline. Transl Res 2020;221:58–64.

[38] Chu NM, Xue Q-L, McAdams-DeMarco MA, et al. Frailty-a risk factor of global and domain-specific cognitive decline among a nationally representative sample of community-dwelling older adult U.S. Medicare beneficiaries. Age Ageing 2021;50:1569–77.

[39] Huang P, Zhang M. Magnetic resonance imaging studies of neurodegenerative disease: from methods to translational research. Neurosci Bull 2023;39:99–112.

[40] Kakimoto A, Ito S, Okada H, et al. Age-related sex-specific changes in brain metabolism and morphology. J Nucl Med 2016;57:221–5.

[41] Pini L, Pievani M, Bocchetta M, et al. Brain atrophy in Alzheimer’s disease and aging. Ageing Res Rev 2016;30:25–48.

[42] Habes M, Pomponio R, Shou H, et al; iSTAGING consortium, the Preclinical AD consortium, the ADNI, and the CARDIA studies. The Brain Chart of Aging: machine-learning analytics reveals links between brain aging, white matter disease, amyloid burden, and cognition in the iSTAGING consortium of 10,216 harmonized MR scans. Alzheimers Dement 2021;17:89–102.

[43] Habes M, Erus G, Toledo JB, et al. White matter hyperintensities and imaging patterns of brain ageing in the general population. Brain 2016;139:1164–79.

[44] Huang CC, Chou K-H, Lee W-J, et al. Brain white matter hyperintensities-predicted age reflects neurovascular health in middle-to-old aged subjects. Age Ageing 2022;51:1–10.

[45] Montandon ML, Herrmann FR, Garibotto V, et al. Microbleeds and medial temporal atrophy determine cognitive trajectories in normal aging: a longitudinal PET-MRI study. J Alzheimers Dis 2020;77:1431–42.

[46] Lim JS, Hong K-S, Kim G-M, et al. Cerebral microbleeds and early recurrent stroke after transient ischemic attack: results from the Korean Transient Ischemic Attack Expression Registry. JAMA Neurol 2015;72:301–8.

[47] Leal SL, Yassa MA. Perturbations of neural circuitry in aging, mild cognitive impairment, and Alzheimer’s disease. Ageing Res Rev 2013;12:823–31.

[48] Sala-Llonch, R, Bartrés-Faz D, Junqué C. Reorganization of brain networks in aging: a review of functional connectivity studies. Front Psychol 2015;6:663.

[49] Marstaller L, Williams M, Rich A, et al. Aging and large-scale functional networks: white matter integrity, gray matter volume, and functional connectivity in the resting state. Neuroscience 2015;290:369–78.

[50] Li X, Kehoe EG, McGinnity TM, et al. Modulation of effective connectivity in the default mode network at rest and during a memory task. Brain Connect 2015;5:60–7.

[51] Loessner A, Alavi A, Lewandrowski KU, et al. Regional cerebral function determined by FDG-PET in healthy volunteers: normal patterns and changes with age. J Nucl Med 1995;36:1141–9.

[52] Yoshizawa H, Gazes Y, Stern Y, et al. Characterizing the normative profile of 18F-FDG PET brain imaging: sex difference, aging effect, and cognitive reserve. Psychiatry Res 2014;221:78–85.

[53] Yanase D, Matsunari I, Yajima K, et al. Brain FDG PET study of normal aging in Japanese: effect of atrophy correction. Eur J Nucl Med Mol Imaging 2005;32:794–805.

[54] Pagani M, Giuliani A, Öberg J, et al. Progressive disintegration of brain networking from normal aging to Alzheimer disease: analysis of independent components of (18)F-FDG PET Data. J Nucl Med 2017;58:1132–9.

[55] Li Y, Choi WJ, Wei W, et al. Aging-associated changes in cerebral vasculature and blood flow as determined by quantitative optical coherence tomography angiography. Neurobiol Aging 2018;70:148–59.

[56] Huang S, Wang YJ, Guo J. Biofluid biomarkers of Alzheimer’s disease: progress, problems, and perspectives. Neurosci Bull 2022;38:677–91.

[57] Chiu MJ, Fan L-Y, Chen T-F, et al. Plasma tau levels in cognitively normal middle-aged and older adults. Front Aging Neurosci 2017;9:51.

[58] Cantero JL, Atienza M, Ramos-Cejudo J, et al. Plasma tau predicts cerebral vulnerability in aging. Aging (Albany NY) 2020;12:21004–22.

[59] Cavedo, E, Lista S, Houot M, et al., Alzheimer Precision Medicine Initiative; INSIGHT-preAD Study Group. Plasma tau correlates with basal forebrain atrophy rates in people at risk for Alzheimer disease. Neurology 2020;94:e30–41.

[60] Kaeser S et al. A neuronal blood marker is associated with mortality in old age. Nature Aging 2021;1:218–225.

[61] Dittrich A, Ashton NJ, Zetterberg H, et al. Plasma and CSF NfL are differentially associated with biomarker evidence of neurodegeneration in a community-based sample of 70-year-olds. Alzheimers Dement (Amst) 2022;14:e12295.

[62] Khalil M, Pirpamer L, Hofer E, et al. Serum neurofilament light levels in normal aging and their association with morphologic brain changes. Nat Commun 2020;11:812.

[63] Henjum K, Almdahl IS, Årskog V, et al. Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease. Alzheimers Res Ther 2016;8:17.

[64] Tsai HH, Chen Y-F, Yen R-F, et al. Plasma soluble TREM2 is associated with white matter lesions independent of amyloid and tau. Brain 2021;144:3371–80.

[65] Park SH, Lee E-H, Kim H-J, et al. The relationship of soluble TREM2 to other biomarkers of sporadic Alzheimer’s disease. Sci Rep 2021;11:13050.

[66] Zhao A, Jiao Y, Ye G, et al. Soluble TREM2 levels associate with conversion from mild cognitive impairment to Alzheimer’s disease. J Clin Invest 2022;132:1–11.

[67] Abdelhak A, Hottenrott T, Morenas-Rodríguez E, et al. Glial activation markers in CSF and serum from patients with primary progressive multiple sclerosis: potential of serum GFAP as disease severity marker? Front Neurol 2019;10:280.

[68] Abdelhak A, Foschi M, Abu-Rumeileh S, et al. Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat Rev Neurol 2022;18:158–72.

[69] Korley FK, Jain S, Sun X, et al; TRACK-TBI Study Investigators. Prognostic value of day-of-injury plasma GFAP and UCH-L1 concentrations for predicting functional recovery after traumatic brain injury in patients from the US TRACK-TBI cohort: an observational cohort study. Lancet Neurol 2022;21:803–13.

[70] Krekoski CA, Parhad IM, Fung TS, et al. Aging is associated with divergent effects on Nf-L and GFAP transcription in rat brain. Neurobiol Aging 1996;17:833–41.

[71] Anderson CP, Rozovsky I, Stone DJ, et al. Aging and increased hypothalamic glial fibrillary acid protein (GFAP) mRNA in F344 female rats. Dissociation of GFAP inducibility from the luteinizing hormone surge. Neuroendocrinology 2002;76:121–30.

[72] Wruck W, Adjaye J. Meta-analysis of human prefrontal cortex reveals activation of GFAP and decline of synaptic transmission in the aging brain. Acta Neuropathol Commun 2020;8:26.

[73] Bettcher BM, Olson KE, Carlson NE, et al. Astrogliosis and episodic memory in late life: higher GFAP is related to worse memory and white matter microstructure in healthy aging and Alzheimer’s disease. Neurobiol Aging 2021;103:68–77.

[74] Han X, Lei Q, Xie J, et al. Potential regulators of the senescence-associated secretory phenotype during senescence and aging. J Gerontol A Biol Sci Med Sci 2022;77:2207–18.

[75] Wang P, Yu Le, Gong J, et al. An activity-based fluorescent probe for imaging fluctuations of peroxynitrite (ONOO(-)) in the Alzheimer’s disease brain. Angew Chem Int Ed Engl 2022;61:e202206894.

[76] Ono T, Uehara Y, Kurishita A, et al. Biological significance of DNA methylation in the ageing process. Age Ageing 1993;22:S34–43.

[77] Junnila RK, List EO, Berryman DE, et al. The GH/IGF-1 axis in ageing and longevity. Nat Rev Endocrinol 2013;9:366–76.

[78] Liu XM, Chan HC, Ding G-L, et al. FSH regulates fat accumulation and redistribution in aging through the Gαi/Ca(2+)/CREB pathway. Aging Cell 2015;14:409–20.

[79] Schafer MJ, Atkinson EJ, Vanderboom PM, et al. Quantification of GDF11 and myostatin in human aging and cardiovascular disease. Cell Metab 2016;23:1207–15.

[80] Crunkhorn S. Aging: promoting NAD(+) production. Nat Rev Drug Discov 2018;17:864.

[81] Paixao L, Sikka P, Sun H, et al. Excess brain age in the sleep electroencephalogram predicts reduced life expectancy. Neurobiol Aging 2020;88:150–5.

[82] Baecker L, Garcia-Dias R, Vieira S, et al. Machine learning for brain age prediction: introduction to methods and clinical applications. EBioMedicine 2021;72:103600.

[83] Yook S, Park HR, Park C, et al. Novel neuroelectrophysiological age index associated with imaging features of brain aging and sleep disorders. Neuroimage 2022;264:119753.

[84] Liem F, Varoquaux G, Kynast J, et al. Predicting brain-age from multimodal imaging data captures cognitive impairment. Neuroimage 2017;148:179–88.

[85] Millar PR, Gordon BA, Luckett PH, et al. Multimodal brain age estimates relate to Alzheimer disease biomarkers and cognition in early stages: a cross-sectional observational study. Elife 2023;12:1–25.

RIGHTS & PERMISSIONS

2023 The Author(s) 2023. Published by Oxford University Press on behalf of Higher Education Press.